

9/913020

PATENT

ATTORNEY DOCKET NO.: 056291-5019

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re PATENT APPLICATION of:	)	
	)	
HENNEQUIN et al.	)	
	)	
Appln. No.: 09/913,020	)	Group Art Unit:
	)	
Filed: August 9, 2001	)	Examiner:
	)	
FOR: QUINAZOLINE DERIVATIVES AS	)	
ANGIOGENESIS INHIBITORS	)	

Commissioner of Patents  
Washington, D.C. 20231

Date: May 6, 2002

Sir:

**PRELIMINARY AMENDMENT**

Prior to examination of the above-identified application on the merits, please amend the application as follows:

**IN THE SPECIFICATION:**

Please replace the subparagraphs reciting the definitions of R<sup>2</sup> and R<sup>1</sup> from page 3, line 19 to page 9, line 23, with the following amended subparagraphs:

A<sub>2</sub> R<sup>2</sup> represents hydrogen, hydroxy, halogeno, cyano, nitro, trifluoromethyl, C<sub>1-3</sub>alkyl, C<sub>1-3</sub>alkoxy, C<sub>1-3</sub>alkylsulphanyl, -NR<sup>3</sup>R<sup>4</sup> (wherein R<sup>3</sup> and R<sup>4</sup>, which may be the same or different, each represents hydrogen or C<sub>1-3</sub>alkyl), or R<sup>5</sup>X<sup>1</sup>- (wherein X<sup>1</sup> represents a direct bond, -O-, -CH<sub>2</sub>-, -OC(O)-, -C(O)-, -S-, -SO-, -SO<sub>2</sub>-, -NR<sup>6</sup>C(O)-, -C(O)NR<sup>7</sup>-, -SO<sub>2</sub>NR<sup>8</sup>-, -NR<sup>9</sup>SO<sub>2</sub>- or -